Hartmutj Ehrlich News Today

EQS-News: ABIVAX / Key word: Miscellaneous Abivax: Publication of an expert article in JCC on obefazimod as promising therapeutic management option for UC patients 02.05.2023 /... | May 2, 2023

The authors of the expert article published in the Journal of Crohn's and Colitis include major European and North American Key Opinion Leaders in the field of Inflammatory Bowel DiseasesThe KOLs state

Abivax: Publication of an Expert Article in JCC on Obefazimod as Promising ...

EQS-News: ABIVAX / Key word(s): MiscellaneousAbivax: Publication of an expert article in JCC on obefazimod as promising therapeutic management option for UC patients 02.05.2023 / 18:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Abivax: Publication of an expert article in JCC on obe...

Interviews with the CEOs of Six Biotech Companies, with Six Strategies to achieve success with their stocks

The results show 52.5% of patients achieved clinical remission at week 96, while 59.0% saw endoscopic improvement, 35.9% achieved endoscopic remission, and 70.5% achieved a clinical response.

EQS-News: ABIVAX / Key word: Annual Results Abivax reports 2022 financial results and operations update 19.04.2023 / 21:00 CET/CEST The issuer is solely responsible for the... | April 19, 2023

Obefazimod global pivotal phase 3 program (ABTECT program) in moderate to severe ulcerative colitis (UC) early enrollment progressing according to planAbivax reports promising Phase 2b maintenance results

Abivax Reports 2022 Financial Results and Operations Update

19.04.2023 - EQS-News: ABIVAX / Key word(s): Annual Results Abivax reports 2022 financial results and operations update 19.04.2023 / 21:00 CET/CEST The issuer is solely responsible for the content of this announcement. Abivax reports 2022 financial results and ...